06 Nov Targeting the “untargetable”: The inhibition of the transcription factor FOXC1 with CRISPR-Cas9 ribonucleoproteins reduces triple negative breast cancer aggressiveness in vitro

Posted at 13:40h in INNOVATIVE THERAPIES by

ID: 03239

Authors: Marqués, Marta (1); Urdanibia, Izaskun (1); Pont, Mariona (1); Hidalgo, Iván (1); Oronich, Arnau (1); Sorolla, Maria Alba (1); Parisi, Eva (1); Montal, Robert (2); Salud, Antonieta (2); Sorolla, Anabel (1)

Topic: INNOVATIVE THERAPIES